Skip to main content
Clinical Trials/ACTRN12620001070921
ACTRN12620001070921
Not yet recruiting
未知

Evaluating the Effect of Transesophageal Echocardiography (TOE)- Guided Device Lead Positioning on the development of new or worsening tricuspid regurgitation – the REDUCE-TR Study.

Royal Prince Alfred Hospital0 sites125 target enrollmentOctober 19, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Royal Prince Alfred Hospital
Enrollment
125
Status
Not yet recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 19, 2020
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Clinical indication for device implantation (permanent pacemaker or debfibrillator)
  • 2\.Greater than or equal to 18 years of age
  • 3\.Able to provide informed consent

Exclusion Criteria

  • 1\.Previous endocardial lead
  • 2\.Moderate or greater tricuspid regurgitation on baseline transthoracic echocardiography
  • 3\.Moderate or severe right ventricular dilatation or systolic dysfunction
  • 4\.Estimated right ventricular systolic pressure \>70mmHg
  • 5\.Suboptimal 3D\-TOE images at time of device\-implantation
  • 6\.Unable to attend 6\-month follow up at a designated echo centre.
  • 7\. Complete heart block
  • 8\. Rapid atrial fibrillation
  • 9\. More than one lead across tricuspid valve planned (E.g. His bundle backup lead)

Outcomes

Primary Outcomes

Not specified

Similar Trials